Ardelyx, Inc.

NasdaqGM:ARDX 株式レポート

時価総額:US$1.3b

Ardelyx 過去の業績

過去 基準チェック /06

Ardelyxは10.5%の年平均成長率で業績を伸ばしているが、Biotechs業界はgrowingで19.3%毎年増加している。売上は成長しており、年平均72.1%の割合である。

主要情報

10.5%

収益成長率

31.8%

EPS成長率

Biotechs 業界の成長17.0%
収益成長率72.1%
株主資本利益率-45.9%
ネット・マージン-28.8%
前回の決算情報30 Sep 2024

最近の業績更新

Recent updates

Ardelyx Lost The Lawsuit, But The Kidney PATIENT Act Will Save It

Nov 24

Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability

Nov 14

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Nov 03
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Oct 24
Ardelyx, Inc.'s (NASDAQ:ARDX) Shares Lagging The Industry But So Is The Business

Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Aug 25
Is Ardelyx (NASDAQ:ARDX) Weighed On By Its Debt Load?

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 07
Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Ardelyx Faces Rising Challenges Despite Revenue Growth

Aug 05

Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Aug 04
Earnings Beat: Ardelyx, Inc. (NASDAQ:ARDX) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Ardelyx: Increased Focus On Ibsrela Due To Xphozah's Uncertain Outlook

Jul 13

Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Jul 05
Why Investors Shouldn't Be Surprised By Ardelyx, Inc.'s (NASDAQ:ARDX) 25% Share Price Plunge

Ardelyx: Strong Execution, Fairly Valued

May 10

Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

May 04
Ardelyx, Inc. (NASDAQ:ARDX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Ardelyx Stock: A Crowded Market Curbs The Enthusiasm (Rating Downgrade)

May 03

Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Apr 17
Ardelyx, Inc.'s (NASDAQ:ARDX) Popularity With Investors Is Under Threat From Overpricing

Ardelyx Shrugs Off 'Mixed' Q4 Earnings

Mar 13

Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Feb 24
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts

Ardelyx Q4 Preview: Recent Bull Run May Pause While Market Digests 2024 Guidance

Feb 20

Ardelyx's XPHOZAH Still An Afterthought To The Pros

Jan 31

Ardelyx: FDA Approval For Xphozah Grants Further Sales Enhancement

Jan 10

Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Jan 04
Ardelyx, Inc.'s (NASDAQ:ARDX) Business Is Yet to Catch Up With Its Share Price

Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Dec 14
Despite Lacking Profits Ardelyx (NASDAQ:ARDX) Seems To Be On Top Of Its Debt

Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Aug 03
Party Time: Brokers Just Made Major Increases To Their Ardelyx, Inc. (NASDAQ:ARDX) Earnings Forecasts

Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Jul 31
Rock star Growth Puts Ardelyx (NASDAQ:ARDX) In A Position To Use Debt

Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Apr 17
Pinning Down Ardelyx, Inc.'s (NASDAQ:ARDX) P/S Is Difficult Right Now

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Mar 30
Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

Dec 14
Is Ardelyx (NASDAQ:ARDX) Using Debt Sensibly?

What To Expect For Ardelyx In The Coming Month

Oct 18

収支内訳

Ardelyx の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NasdaqGM:ARDX 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Sep 24252-732300
30 Jun 24210-651980
31 Mar 24159-661610
31 Dec 23124-661340
30 Sep 23134-271060
30 Jun 2383-56920
31 Mar 2363-66840
31 Dec 2252-67770
30 Sep 229-114750
30 Jun 225-135730
31 Mar 224-153750
31 Dec 2110-158690
30 Sep 2111-151660
30 Jun 2112-125560
31 Mar 2113-105430
31 Dec 208-94330
30 Sep 208-85290
30 Jun 208-91280
31 Mar 206-91260
31 Dec 195-95240
30 Sep 193-1032322
30 Jun 190-1042240
31 Mar 190-1002356
31 Dec 183-91240
30 Sep 1845-532464
30 Jun 1844-502462
31 Mar 1844-532366
31 Dec 1742-642375
30 Sep 170-10623150
30 Jun 170-11421134
31 Mar 170-11721114
31 Dec 160-1121994
30 Sep 160-98180
30 Jun 160-87170
31 Mar 1618-50150
31 Dec 1524-301439
30 Sep 1530-16120
30 Jun 15382110
31 Mar 1529-690
31 Dec 1432-370
30 Sep 1434-461
30 Jun 1433-553
31 Mar 1431-756
31 Dec 1329-740

質の高い収益: ARDXは現在利益が出ていません。

利益率の向上: ARDXは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: ARDXは利益を出していないが、過去 5 年間で年間10.5%の割合で損失を削減してきた。

成長の加速: ARDXの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: ARDXは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。


株主資本利益率

高いROE: ARDXは現在利益が出ていないため、自己資本利益率 ( -45.85% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘